Clinical Efficacy of Toprazolin Hydrochloride Injection in the Treatment of Neonatal Persistent Pulmonary Hypertension
This paperanalyse the clinical efficacy and safety of tolazoline hydrochloride injection in the treatment of neonatal persistent pulmonary hypertension.The routine group was treated with sildenafil tablets, while the experimental group was too difficult to treat torazolin hydrochloride injection on the basis of the routine group. The effective rate of clinical treatment was 92.00% (46/50) in the experimental group and 66.00% (33/50) in the conventional group, which was significantly higher in the experimental group than in the conventional group (P < 0.05). There were significant differences in the data and the results were significant (P < 0.05). Before treatment, there was no significant difference in different indexes between the two groups, and the comparison results were meaningless (P > 0.05). After treatment, the indexes of the experimental group were significantly better than those of the conventional group, and the difference of data was significant (P < 0.05). The fever disappearance time, cough disappearance time and lung rale disappearance time of the experimental group were significantly lower than those of the conventional group, the data difference was prominent, and the comparison results were significant (P < 0.05). The incidence of nausea, vomiting, abdominal pain, diarrhea and injection site pain in the experimental group was significantly lower than that in the conventional group, and the difference was significant (P < 0.05). Torazolin hydrochloride injection is a safe and effective treatment for neonatal persistent pulmonary hypertension. It can effectively improve clinical symptoms and optimize vital signs. It is worth popularizing in clinical practice.